Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?

Patients with EGFR-mutant non–small cell lung cancer achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR-targeted therapy. Investigation into the mechanisms underlying this intriguing association is needed.

See related article by Offin et al., p. 1063

http://bit.ly/2sXT6Ap